{"id":"NCT00401193","sponsor":"Ferring Pharmaceuticals","briefTitle":"Efficacy and Safety of XP12B in Women With Menorrhagia","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study To Evaluate Efficacy and Safety of XP12B for the Treatment of Menorrhagia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2006-11-20","resultsPosted":"2010-02-24","lastUpdate":"2015-05-13"},"enrollment":304,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Menorrhagia","Heavy Menstrual Bleeding"],"interventions":[{"type":"DRUG","name":"Tranexamic acid tablets","otherNames":["Lysteda","XP12B"]},{"type":"DRUG","name":"Tranexamic acid tablets","otherNames":["Lysteda","XP12B"]},{"type":"DRUG","name":"Placebo tablets","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.","primaryOutcome":{"measure":"Mean Reduction From Baseline in Menstrual Blood Loss (MBL)","timeFrame":"Baseline MBL over 3 menstrual cycles","effectByArm":[{"arm":"3900 mg/Day","deltaMin":65,"sd":51},{"arm":"1950 mg/Day","deltaMin":44,"sd":57},{"arm":"Placebo","deltaMin":7,"sd":46}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":83,"countries":["United States"]},"refs":{"pmids":["21777897","20942615"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":115},"commonTop":["Headache","Abdominal Pain","Nasal & Sinus Symptoms","Back Pain","Musculoskeletal Pain"]}}